東方盛虹(000301.SZ):擬投資60.34億元建POSM及多元醇項目
格隆匯5月14日丨東方盛虹(000301.SZ)公佈,公司為充分發揮煉化產業鏈規模化、一體化的平台作用,進一步豐富煉化產品結構,提高產品附加值,提升公司綜合競爭實力,下屬三級子公司江蘇虹威化工有限公司(“虹威化工”)將投資建設POSM 及多元醇項目。該項目預計總投資為人民幣60.34億元,建設期為3年。
該項目範圍包括乙苯(EB)、環氧丙烷/苯乙烯(POSM)、聚醚多元醇(PPG)和聚合物多元醇(POP)等工藝裝置、配套公用工程及生產輔助設施。乙苯裝置規模:50.8萬噸/年,POSM裝置規模:20/45萬噸/年,PPG裝置規模:11.25萬噸/年,POP裝置規模:2.5萬噸/年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.